ClinicalTrials.gg
RecruitingNCT06639503Updated Feb 5, 2026

Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau

A Phase 1 interventional study of Bupivacain in Tibial Plateau Fractures, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by University of Chicago · Phase 1, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Tibial Plateau Fractures with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Tibial Plateau Fractures · United States.

Planned enrollment
6th of 10
38 · median 54
Started
2024
the only one that year
Phase 1
4 of 11
2 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
University of Chicago

Among the 11 studies in Tibial Plateau Fractures with a site in United States, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 4 in phase 1, and was the 10th registered.

Tibial Plateau Fractures

33 studies on the registry are indexed under Tibial Plateau Fractures; 13 are open to participants now.

Browse Tibial Plateau Fractures studies →

Open to participants now

3 of the 11 studies in Tibial Plateau Fractures with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Tibial Plateau Fractures studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Tibial Plateau Fractures with a site in United States, or all of them as a file.
02

Study summary

The investigators are conducting this research study to find better ways of treating pain following knee surgery. There is a standard (accepted) approach, which involves injection of numbing medication into the area around the participant surgical incision. The investigators hope to discover if providing numbing medication to a nerve that controls pain in a larger area of the knee (a nerve block), might be better at post-operative pain control.

Read the detailed description

The investigators are conducting this research study to find better ways of treating pain following knee surgery like the one the participant will be having. There is a standard (accepted) approach, which involves injection of numbing medication into the area around the participant surgical incision. The investigators hope to discover if providing numbing medication to a nerve that controls pain in a larger area of the knee (a nerve block), might be better at post-operative pain control. This type of nerve block is commonly used to treat other knee pains, like that associated with arthritis, after knee replacements, and after repairs of the knee ligaments; however, it is considered experimental in your case, as its effects (good or bad) are unknown in the type of knee surgery the participant are undergoing.

The investigators plan is to decide at random, like the flip of a coin, whether to give numbing medication (0.25% bupivacaine) around the incision like the investigators normally would or give it instead to block the pain sensors around the knee. The participant would get medication either at the incision (shin) or the knee, depending on which arm the participant are in (research). The participant will also be given pain medication pills by your surgeon as part of the participant normal postoperative care (not research).

03

Conditions studied

  • Tibial Plateau Fractures

Keywords

  • peri-incisional local anesthesia
  • genicular nerve block
  • Tibial Plateau Fractures
  • open reduction internal fixation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any adult patient (ages 18 and over) undergoing open reduction internal fixation of an acute isolated tibial plateau fracture

Exclusion criteria

Exclusion Criteria:

  • Subjects younger than 18
  • Polytraumatized Subjects
  • Subjects with pathologic fractures
  • Subjects with tibial plateau fractures treated nonoperatively
  • Subjects with tibial plateau fractures treated operatively but with re-operations at the same site
  • Subjects with open fractures
  • Subjects with fracture-dislocations
  • Subjects with active or history of anxiety
  • Subjects with visual analog scale anxiety score ≥ 7 measured preoperatively
  • Subjects with chronic pain syndromes
  • Subjects with chronic opioid use
  • Subjects with illicit drug use disorder
  • Subjects with alcohol abuse disorder
  • Subjects with kidney disease precluding use of ketorolac
  • Subjects with liver disease precluding the use of acetaminophen
  • Subjects with allergy to acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opiates or local anesthesia
  • Subjects with inability to provide a visual analog scale score postoperatively
  • Subjects with to receiving peripheral nerve blocks, including relevant neurologic deficits, active infection at sites of injections - re-operation at the same site
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
38 participants (estimated)

Study arms

  • No intervention
    Peri-incisional local anesthesia

    subjects randomized to peri-incisional local anesthesia administration will receive an injection of 25 ml of 0.25% bupivacaine across all incisions at the time of wound closure (standard of care)

  • Experimental
    Genicular nerve blockade

    Subjects randomized to genicular nerve block will receive a fluoroscopic guided injection of 5 ml of 0.25% bupivacaine at the described locations of the superolateral genicular nerve, super medial genicular nerve, inferomedial genicular nerve, recurrent fibular nerve, and infrapatellar branch of the saphenous nerve under fluoroscopic guidance at the time of wound closure

    Drug: Bupivacain

Interventions

06

What researchers measure

Primary outcomes

  1. Pain Ratings from Visual Analog Scale (VAS)

    To determine if genicular nerve blockade after open reduction internal fixation of tibial plateau fractures compared to standard care of peri-incisional local anesthetic leads to decreased pain as measured by visual analog scale at one hour postoperatively, two hours postoperatively, and at Post Anesthesia Care Unit (PACU) discharge. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')

    Time frame: one hour, two hours, and discharge from PACU

Secondary outcomes

  1. Comparing blocks

    To assess the effect of genicular nerve block compared to standard peri-incisional local anesthetic on analgesic consumption in the Post Anesthesia Care Unit (PACU) using they Visual analog (VAS) scale. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')

    Time frame: one hour after surgery, 2 hours after surgery, and discharge from PACU

  2. Block effect on range of motion

    To assess the effect of genicular nerve block compared to standard peri-incisional local anesthetic on postoperative function as assessed by postoperative knee range of motion at time of Post Anesthesia Care Unit (PACU) discharge.

    Time frame: PACU discharge

  3. VAS score daily first three days after surgery

    To determine the effect of genicular nerve block compared to standard peri-incisional local anesthetic on pain control for the first three days after surgery as measured by the visual analog scale. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')

    Time frame: daily for three days after surgery

  4. Brief pain inventory (short scale) daily first three days after surgery

    To determine the effect of genicular nerve block compared to standard peri-incisional local anesthetic on pain control for the first three days after surgery as measured by the Brief pain inventory (short scale). the brief pain inventory (Short form) uses a 0 to 10 numeric rating scales for item rating. 1 - 4 = Mild Pain 5 - 6 = Moderate Pain 7 - 10 = Severe Pain

    Time frame: daily first three days after surgery

  5. effect of genicular nerve blockade compared to standard peri-incisional local anesthetic

    To determine the effect of genicular nerve blockade compared to standard peri-incisional local anesthetic on opiate use as determined by the number of prescription opiate pain pills remaining at 2 weeks post surgery.

    Time frame: 2 weeks post surgery

  6. Comparing blocks

    To assess the effect of genicular nerve block compared to standard peri-incisional local anesthetic on analgesic consumption in the Post Anesthesia Care Unit (PACU) using the Brief pain inventory (short form). the brief pain inventory (Short form) uses a 0 to 10 numeric rating scales for item rating. 1 - 4 = Mild Pain 5 - 6 = Moderate Pain 7 - 10 = Severe Pain

    Time frame: daily first three days after surgery

  7. Comparing blocks

    To assess the effect of genicular nerve block compared to standard peri-incisional local anesthetic on analgesic consumption in the Post Anesthesia Care Unit (PACU) using opiate pill counts.

    Time frame: 2 weeks after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan to share individual participant data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Sep 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Sep 1, 2026
CompletionEst.
Oct 14, 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06639503
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Nov 1, 2024
Primary completion
Sep 1, 2026 (estimated)
Completion
Oct 14, 2026 (estimated)
Last update
Feb 5, 2026

Study contacts

Anthony Christiano, MD
Contact
anthony.christiano@bsd.uchicago.edu
773-834-3531
Anthony Christiano, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion